

## Impact of Age on Hypermutation of Immunoglobulin Variable Genes in Humans

KARLI ROSNER,<sup>1,2</sup> DAVID B. WINTER,<sup>1</sup> CYNTHIA KASMER,<sup>1</sup> GUNHILD LANGE SKOVGAARD,<sup>2,3</sup> ROBERT E. TARONE,<sup>4</sup> VILHELM A. BOHR,<sup>1</sup> and PATRICIA J. GEARHART,<sup>1,5</sup>

Accepted: December 14, 2000

Chronological aging is associated with an accumulation of DNA mutations that results in cancer formation. The effect of aging on spontaneous mutations in humans is difficult to study because mutations are infrequent in the overall genome and tumors are relatively rare. In contrast, somatic mutations in immunoglobulin variable genes are abundant and can be studied in peripheral blood lymphocytes. To determine if aging alters the frequency and pattern of hypermutation, we sequenced 331 cDNA clones with rearranged V<sub>H</sub>6 genes and compared 452 mutations from young humans to 570 mutations from old humans. There were more mutated clones in the young population compared to the old population. Among the mutated clones, the frequency, location, and types of substitutions were similar between the young and the old groups. However, the ratio of replacement-to-silent mutations was much higher in the complementarity-determining regions of heavy chains from old people, which indicates that their B cells had been selected by antigen. Among individuals, there was variability in the frequency of tandem mutations, which we have observed in mice defective for the PMS2 mismatch repair protein. Microsatellite variability in DNA, which is caused by impaired mismatch repair, was then measured, and there was a strong correlation between the frequency of tandem mutations and microsatellite alterations. The data suggest that individuals vary in their mismatch repair capacity, which can affect the mutational spectra in their antibodies.

**KEY WORDS:** Immunoglobulin genes; hypermutation; aging; antibody selection; mismatch repair.

### INTRODUCTION

In long-lived organisms, the genomic DNA of somatic cells gradually accumulates mutational changes with time. In humans, this mutational load contributes to the observed increase in cancer incidence with age, and probably to other age-related pathologies (1–3). Mutations throughout most of the genome arise as a consequence of DNA damage that is improperly repaired, as well as from the low intrinsic error rate of the DNA replication machinery. To limit the occurrence of such sequence changes, cells employ pathways such as base excision repair and nucleotide excision repair to remove damage caused by natural DNA decay and by reactive damaging agents of endogenous and extracellular origin (4). In addition, replication errors are minimized through an efficient postreplicative mismatch correction system (5). It is clearly desirable that all of these antimutagenic defense mechanisms are kept intact throughout the lifetime of an individual. If DNA repair were compromised with aging, this could contribute to an increased risk of cancer, as has been suggested from measurements of nucleotide excision repair and skin carcinogenesis in old humans (6).

A striking exception to the general need for limiting mutations is found in B lymphocytes, which use a highly specialized mechanism to introduce nucleotide substitutions into variable (V) genes of immunoglobulins (7). The hypermutation mechanism generates mutations up to a million times more frequently than those introduced by spontaneous mutation. This targeted, high-frequency form of mutagenesis has the purpose of increasing the repertoire of antibodies available for binding to antigens, which can challenge an organism anytime during its life span. Thus, it is preferable that this mechanism for generating antibody diversity is kept intact with age.

Several studies have examined V genes from old mice and humans to determine if they have hypermutation,

<sup>1</sup>Laboratory of Molecular Genetics, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224.

<sup>2</sup>Laboratory of Molecular Gerontology and Dermatology, Rigshospitalet, Copenhagen, Denmark.

<sup>3</sup>Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.

<sup>4</sup>Biostatistics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

<sup>5</sup>To whom correspondence should be addressed at Laboratory of Molecular Genetics, National Institute on Aging, NIH, 5600 Nathan Shock Drive, Baltimore, Maryland 21224. Fax: 410-558-8157.

and the results have been variable. Old mice do not mount a strong *de novo* immune response following deliberate immunization (8–10). However, B cells from Peyer's patches of old mice produce mutated antibodies (11), suggesting that memory B cells specific for environmental antigens are adequately stimulated in old animals (12). Different experimental approaches may explain the discrepancy in data from old humans. Thus, decreased frequencies of mutation were found in genes from B cells from nonvaccinated old subjects (13–15). In contrast, similar frequencies of mutation in young and old people were observed in cDNA clones of RNA made by activated cells (16–18) and from DNA from intestinal B cells responding to environmental antigens (19). Another confounding issue is that vaccination to influenza is common among the elderly population in the United States compared to Europe, and this may increase selection for specific antibodies. Furthermore, none of these studies made a detailed comparison of the spectrum of V gene mutations to see if the pattern and types of substitutions change with age.

The Baltimore Longitudinal Study on Aging provides a unique and valuable resource of documented blood samples from persons of different ages. Using this material, we collected a large database of V gene sequences from a sample of young and old humans, and performed an extensive analysis of the frequency and pattern of V gene mutations. We then searched for correlations between properties of the mutation pattern and microsatellite variability, which is an indicator of general genome instability.

## MATERIALS AND METHODS

### *Study Participants*

Five young and five old individuals, 26–29 and 81–86 years of age, respectively, were participants in the Baltimore Longitudinal Study on Aging program at the Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD. The protocol was approved by the Institutional Review Board for Human Subjects Research of the Johns Hopkins Bayview Medical Center. Three people in the young group, Y1, Y3, and Y4, and four people in the old group, O1, O3, O4, and O5, were females. None of the participants expressed an acute illness at the time of blood removal. Subject Y5 was under treatment for asthma and allergic skin reactions with histamine and steroid creams, and subject O5 was under treatment for polymyalgia rheumatica with oral prednisone. The five old people

were immunized against influenza during the 10 months prior to blood removal; the young people were not immunized during that time.

### *Blood Collection, RNA and DNA Preparation*

Twenty milliliters of peripheral blood was collected in EDTA. Mononuclear cells were isolated by centrifugation through Ficoll–Paque Plus (Amersham Life Science Inc., Arlington Heights, IL), and total RNA was extracted using RNA STAT-60 (Tel-Test B, Inc., Friendswood, TX). To make cDNA, 0.25 µg of RNA was transcribed with Superscript II reverse transcriptase (Life Technologies, Gaithersburg, MD) and a reverse primer complementary to the mRNA starting at codon 264 in the C<sub>H</sub>2 exon of the constant (C) gene for IgM (20), 5'AAGAAGCCGTCGCGGGGTGG. DNA was extracted from a portion of the cells with phenol and chloroform, precipitated with ethanol, and resuspended in 50 µg per ml of 10 mM Tris–1 mM EDTA, pH7.6.

### *cDNA Cloning and Sequencing*

The cDNA was amplified in a 50-µl reaction containing half of the cDNA, *Pfu* DNA polymerase (Stratagene, La Jolla, CA), a forward first primer for the leader region of the V<sub>H</sub>6 gene starting at codon–19 (21), 5'TCTGTCTCCTTCCTCATCTTC, and the reverse first primer shown above. The amplification consisted of 30 cycles of denaturation at 95°C for 1 min, annealing at 64°C for 2 min, and extension at 72°C for 3 min, followed by a final incubation at 72°C for 10 min. Two microliters of the reaction was then amplified for another 30 cycles using a second set of nested primers containing restriction sites for cloning. The forward second primer started at codon –10 in the leader region and contained a *Bam*HI site, 5'CGCGGATCCGCCCCGTGCTGGGCTCCCATG; and the reverse second primer started at codon 223 in C<sub>H</sub>1 in the C<sub>µ</sub> gene and contained a *Hind*III site, 5'TGGAAGCTTCACGTTCTTTTCTTTGTTGCC. The 670-bp PCR products containing both V and C genes were cloned into restriction-digested M13mp18, and viral plaques containing inserts were identified by hybridization to a V<sub>H</sub>6-specific oligonucleotide. Viral DNA with rearranged V<sub>H</sub>6 genes were sequenced with a primer starting at codon 140 in C<sub>H</sub>1 of the C<sub>µ</sub> gene, 5'AACGGCCACGCTGCTCGTATC, and with successive primers located across the V<sub>H</sub>6 gene. C<sub>H</sub>1 exons were sequenced with a M13 primer starting at the *Hind*III site.

### Microsatellite Variability

The concentration of DNA from peripheral blood lymphocytes was determined by optical density, and samples were diluted to 5 pg/ $\mu$ l. The D2S123 microsatellite containing a dinucleotide repeat on chromosome 2 was amplified with a forward primer, 5'AAACAGGATGCCTGCCTTTA, and a reverse primer, 5'GGACTT-TCCACCTATGGGAC (22). To detect accurately an infrequent change in size of a microsatellite, the DNA concentrations were adjusted so that only one positive PCR product was obtained in three reactions. The 20- $\mu$ l reactions contained 1–10 pg of DNA, 80 ng of the forward primer, 80 ng of the reverse primer, 1 nmol each of dATP, dCTP, dGTP, and dTTP, 0.66 pmol of [ $\alpha$ - $^{32}$ P]dCTP at 3000 Ci/mmol (Amersham Life Science Inc., Arlington Heights, IL), 0.2  $\mu$ l of Platinum *Taq* DNA polymerase (Life Technologies, Gaithersburg, MD), and 1 $\times$  PCR buffer with 30 nmol of  $MgCl_2$ . The DNA was amplified in 96-well plates for 30 sec at 95°C, 30 sec at 58°C, and 30 sec at 72°C for 35 cycles. The products were separated on 6% denaturing acrylamide gels with 20% formamide and visualized on a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). Only gels with 35% or less positive lanes were analyzed. The positive reactions were then loaded next to each other on a second gel and separated to identify band shifts.

### Statistical Analyses

The analysis of tandem substitutions is based on comparing the observed number of adjacent mutations to the statistical probability that two mutations will randomly occur next to each other; thus, a large number of mutations in a segment increases the probability for adjacent mutations to occur by chance, and a low number of mutations decreases that probability. The formula for the expected number of tandem substitutions when  $n$  mutations are randomly distributed in a sequence of  $k$  consecutive nucleotides is equal to  $n(n-1)/k$  (23).  $k$  for each FR segment was 90 (FR1), 42 (FR2), 96 (FR3), and 33 (FR4). The comparison of the observed number to the expected number for each age group was based on exact Poisson calculations. Comparisons of the frequency distributions by type of substitution between young and old individuals were performed using Pearson's chi-square test. Because of variability among individuals within age groups, comparisons of mutation frequencies, microsatellite alterations, and the ratios of observed to expected numbers of tandem mutations between old and young individuals were made using the  $t$  test. Pearson correlation coefficients and Spearman rank correlation coefficients

were calculated to measure the relationship between different parameters, and exact tests were employed to determine if correlation coefficients were significantly different from zero. Two-sided  $P$  values are reported for all comparisons.

### RESULTS

The rationale of this study was to compare a large database of mutations from two widely separated age groups to see if age had any effect on somatic hypermutation. Peripheral blood was collected from five people between 26 and 29 years old and five people between 81 and 86 years old, and approximately 25 clones per young individual and 40 clones per old individual were sequenced from cDNA libraries. We focused on the rearranged  $V_H6$  gene associated with IgM heavy (H) chains for the following reasons. First, the  $V_H6$  gene segment is nonpolymorphic (24) and mutations can be easily identified. Second, IgM H chains, which are encoded by the  $C_\mu$  constant gene, are expressed by newly-generated and long-lived B cells in humans, and the analysis would include both de novo and memory mutations.

### Frequency of Mutations

One hundred twenty-eight clones from five young and 203 clones from five old people were analyzed for mutations in the V and J gene segments encoding framework regions (FR) 1–4 and complementarity determining regions (CDR) 1 and 2. Mutations in CDR3 were not identified because of unknown variability introduced during joining of the gene segments. The nucleotide sequences were compared to the germline sequences of the  $V_H6$  gene segment (21),  $J_H$  gene segments (25), and the  $C_H1$  exon of the  $C_\mu$  gene (20) to identify somatic mutations. Mutations at the 3' and 5' ends of V and J gene segments were assigned if they were preceded by two or more consecutive germline nucleotides.

Clones were classified as follows: (a) hypermutated clones had two or more mutations and unique CDR3s, (b) related clones had the same CDR3 sequence with both shared and unique mutations, (c) nonhypermutated clones had zero or one mutation and unique CDR3s, (d) duplicated clones were identical, and (e) hybrid clones from PCR amplification had portions of sequences from different genes. Around 2% of the cDNA clones were nonproductive with stop codons and frameshifts in CDR3 and were not included in further analyses. Of the 126 productive clones sequenced from five young humans, 43% were hypermutated, 13% were related, 27%

were nonhypermutated, 11% were duplicated, and 6% were hybrids. Of the 197 productive clones sequenced from five old humans, 29% were hypermutated, 4% were related, 49% were nonhypermutated, 15% were duplicated, and 3% were hybrids. Among the young people, the percentages of sequenced clones with hypermutation were 28.1, 34.5, 57.9, 56.5, and 47.8% for Y1 through Y5, respectively, with a mean percentage of 45.0% ( $\pm 5.9\%$ ). Among the old people, the percentages were 11.9, 27.8, 22.2, 38.5, and 60.0% for O1 through O5, respectively. If individual O5, who was taking prednisone, is excluded, the mean percentage of mutated clones among the old people is 25.1% ( $\pm 1.2\%$ ), which is significantly lower than that for the young group ( $P = 0.048$ ).

Only the hypermutated clones were considered for further analysis and are listed in Table I. Some 54 clones from young humans and 58 clones from old humans were studied; the number of mutations per clone ranged from 2 to 30. The overall frequency of mutation per base pair for clones from young individuals was 2.4%, and that for clones from old individuals was 2.8%, which is within the normal range of mutations in IgM molecules from peripheral blood (26, 27). There was no statistical difference between these two groups ( $P = 0.20$ ). However, the frequencies were quite homogeneous within the young group ( $P = 0.23$ ) but heterogeneous within the old group ( $P < 10^{-6}$ ). Subject O5 had the lowest frequency, which may be a result of taking prednisone. If O5 is excluded from the analysis, the frequencies are higher for the old population ( $P = 0.05$ ), which could be due to some aspect of aging or influenza vaccination. As a control for *Pfu* polymerase error, the  $C_H1$  exon of the  $C_\mu$  gene was sequenced from 33 clones that had mutations in their V genes. No mutations were found in 6543 bp, corresponding to  $< 2.5 \times 10^{-6}$  mutations per bp per PCR cycle, which is about 200-fold lower than the frequency of mutations in the V genes. Some 99.7% of the mutations were nucleotide substitutions; the rest were one insertion of three nucleotides and two deletions of three and six nucleotides in CDR1, which kept the translation in reading frame. Infrequent insertions and deletions in CDRs 1 and 2 of human V genes have been reported before (28–30) and may be the result of slippage of DNA polymerase during replication or repair.


#### *Distribution of Mutations in the V and J Gene Segments*

The position and types of mutations in the  $V_H6$  gene segment are shown in Fig. 1, which demonstrates the

**Table I.** Number of Mutations in Rearranged  $V_H6$  Genes from Young and Old Humans

Subject	Clone	Number <sup>a</sup>	Subject	Clone	Number
Y1	5122	2	O1	50	2
	5062	4		5	5
	5102	5		82	12
	5123	5		33	21
	5070	6		66	24
	5109	7	O2	37	3
	5035	10		1	7
	5023	11		111	8
	5067	26		21	8
	J016	2		106	8
Y2	J017	3	O3	13	8
	J008	4		191	9
	J031	6		180	12
	J009	6		10	12
	J027	10		34	15
	J037	12		4	21
	J001	14		9	21
	J036	14		88	22
	J013	18		25	22
	4158	2		167	30
Y3	4073	2	O4	6154	3
	4112	2		6074	7
	4086	3		6066	7
	4111	6		6010	7
	4007	6		6052	9
	4001	7		6076	10
	4071	7		6081	12
	4072	8		6018	13
	4136	12		6077	18
	4123	24		6079	18
Y4	7182	3	O5	8004	2
	7011	3		8039	4
	7168	4		8044	4
	7183	4		8003	5
	7160	5		8033	5
	7004	7		8024	7
	7149	7		8007	9
	7177	8		8010	11
	7124	8		8050	13
	7113	11		8043	20
Y5	7107	14		9011	2
	7150	14		9039	2
	7155	19		9028	2
	10	3		9066	2
	2	3		9008	3
	N90	3		9052	4
	N78	3		9072	4
	N15	7		9053	5
	N86	7		9041	7
	N75	10		9067	7
	L79	10		9009	8
	N81	16		9042	9
	L53	18		9029	9
	N66	21		9020	10
				9022	10
				9099	10
				9074	11
				9101	11

<sup>a</sup>Mutations were recorded in rearranged  $V_H6$  and J gene segments; the average length was 347 bp per clone. The average frequency of mutations per base pair for young subjects Y1–Y5 was 2.4% (452 mutations in 18,738 bp), and that for old subjects O1–O5 was 2.8% (570 mutations in 20,126 bp).



**Fig. 1.** Nucleotide sequences of rearranged V<sub>H</sub>6 gene segments in clones from young and old humans. Clones from young individuals are listed above the horizontal line in the top half of the figure, and clones from old individuals are shown below the line. Codon positions are numbered and CDRs are depicted according to Ref. 20. The hot-spot motifs, RGYW and its inverse complement, WRCY, are underlined in the germline sequence. A dash indicates identity to the germline sequence, replacement substitutions are in uppercase, and silent substitutions are in lowercase. (\*) Clones with deletions (D) and insertions (I).


tremendous diversity that is generated by the hypermutation process. Substitutions are noted as either replacement changes, if they change the codon to specify a different amino acid, or silent changes, if they do not change the codon. An illustration of the frequency of mutations per codon is shown in Fig. 2. The distribution of mutations in clones from young people is mirrored by the distribution in clones from old people and shows no difference in the number of mutations and their location in the V gene segment.

Mutations in the J gene segments are shown in Fig. 3. In clones from both young and old individuals, J<sub>H</sub>4 was predominantly utilized, and J<sub>H</sub>1 and J<sub>H</sub>2 were rarely

used, which is consistent with previous studies (18, 25, 31). The overall frequency of mutation per base pair in the FR and CDR regions for both groups is as follows. FR1, 1.2% (123 mutations in 10,170 bp); CDR1, 6.3% (149 mutations in 2373 bp); FR2, 1.1% (51 mutations in 4746 bp); CDR2, 4.8% (293 mutations in 6102 bp); FR3, 2.8% (299 mutations in 10,752 bp); the portion of the J gene segments that comprise CDR3, 4.7% (68 mutations in 1458 bp); and FR4, 0.9% (34 mutations in 3729 bp). Within these regions, there are subregions of hypermutability occurring at residues 31–35 in CDR1 (7.9% mutations/bp), residues 56–61 in CDR2 (9.6% mutations/bp), residues 67–71 in FR3 (6.2% mutations/bp),

CDR2

	50	51	52a	52b	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82a	82b	82c	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478	1479	1480	1481	1482	1483	1484	1485	1486	1487	1488	1489	1490	1491	1492	1493	1494	1495	1496	1497	1498	1499	1500	1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515	1516	1517	1518	1519	15
--	----	----	-----	-----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	----



**Fig. 2.** Average mutational frequency per codon in  $V_H6$  gene segments from young and old humans. Bars represent the percentage mutation calculated by the number of mutations per codon, divided by 3 (nucleotides), divided by the number of clones, multiplied by 100.

#### *Ratios of Replacement-to-Silent Mutations*

The ratios of replacement mutations to silent mutations are higher in the CDRs than in the FRs as a result of selection for B cells exhibiting immunoglobulin receptors with higher affinity for antigen. In Fig. 4, the replacement-to-silent ratios are shown throughout the V gene segment for clones from the young and old groups.  $V_H6$  genes from the old population showed a dramatic increase in replacement changes in CDRs 1 and 2 compared to those from the young population. The differences were significant at residues 31–35 in CDR1 ( $P = 0.004$ ) and residue 56 in CDR2 ( $P = 0.045$ ). Furthermore, a specific tyrosine-to-phenylalanine change at residue 56 occurred nine times in clones from all five old humans and only once in a clone from a young human ( $P = 0.015$ ).

#### *Tandem Mutations and Microsatellite Variability*

We have observed an increased frequency of adjacent mutations in V genes from mice deficient for the PMS2 mismatch repair protein (23). To see if tandem mutations were significantly found in V genes from humans, the observed numbers of tandem mutations were compared to the expected numbers (see Materials and Methods). Only mutations in FRs 1–4 were analyzed, since they are not positively selected for binding to antigen. As shown in Table III, the ratios of observed to expected tandem pairs varied among the individuals but did not differ between the young and the old groups ( $p=0.31$ ). Triplet substitutions were also observed in the sequences but were too infrequent to perform a statistical analysis.

If the accumulation of tandem mutations is related to defective mismatch repair, then the individuals with the

FR4

101																		113																	
		GCT	GAA	TAC	TTC	CAG	CAC	TGG	GGC	CAG	GGC	ACC	CTG	GTC	ACC	GTC	TCC	TCA																	
JH1	O3-6076																																		
	6018																																		
JH3	Y1-5109	AT	GCT	TTT	GAT	ATC		TGG	GGC	CAA	GGG	ACA	ATG	GTC	ACC	GTC	TCT	TCA																	
	Y2-J013																																		
	Y3-4007																																		
	Y4-7177																																		
	7155																																		
	O2- 21																																		
	O5-9052																																		
	9067																																		
	9009																																		
JH4	Y1-5122	AC	TAC	TTT	GAC	TAC		TGG	GGC	CAG	GGA	ACC	CTG	GTC	ACC	GTC	TCC	TCA																	
	5102																																		
	5070																																		
	5035																																		
	5023																																		
	Y2-J008																																		
	J036																																		
	Y3-4073																																		
	4111																																		
	Y4-7183																																		
	7124																																		
	7150																																		
	O1- 50																																		
	66																																		
	O2- 191																																		
	180																																		
	167																																		
	O3-6154																																		
	6010																																		
	6066																																		
	6052																																		
	6081																																		
	6079																																		
	O4-8039																																		
	8010																																		
	8043																																		
	O5-9008																																		
	9042																																		
	9041																																		
	9020																																		
	9022																																		
	9074																																		
JH5	Y3-4001	AC	AAC	TGG	TTT	GAC	CCC	TGG	GGC	CAG	GGA	ACC	CTG	GTC	ACC	GTC	TCC	TCA																	
	4123																																		
	Y5- 10																																		
	L79																																		
	L53																																		
	O1- 33																																		
	O2- 106																																		
	88																																		
	O4-8007																																		
JH6	Y1-5067	AT	TAC	TAC	TAC	TAC	GAT	ATG	GAC	GTC	TGG	GGC	CAA	GGG	ACC	ACG	GTC	ACC	GTC	TCC	TCA														
	Y2-J017																																		
	O2- 111																																		
	10																																		
	4																																		
	O4-8033																																		
	8024*																																		
	O5-9066																																		

Fig. 3. Mutations in  $J_H$  gene segments. Conventions are as in Fig. 1. FR4 is boxed, and (\*) A clone with a different allele of  $J_H6$ , with the allelic nucleotides underlined (25).

highest frequency of tandem mutations should also have increased microsatellite variability. Alterations were analyzed in the CA dinucleotide repeat of the D123S microsatellite on chromosome 2 using DNA from peripheral blood lymphocytes of both the young and the old groups. Examples of altered microsatellites are shown in Fig. 5, which also illustrates the polymorphism at this allele. Individuals Y1, Y3, Y4, Y5, and O3 were homozygous for the locus; Y2, O1, and O2 had alleles that differed by 2 bp; O5 had alleles that differed by 4 bp; and O4 had alleles that differed by 10 bp. Insertions and

deletions of 2 bp (74% of the alterations), 4 bp (15%), and 6 bp (11%) were observed, with deletions occurring twice as frequently as insertions.

The data in Table III show a range of microsatellite variability of 1–6% in the 10 individuals. The assays were repeated several times, with similar results. Microsatellite changes in the young group did not differ from the old group ( $P = 0.31$ ). The tandem ratios were then plotted against the frequencies of altered microsatellites in all 10 humans, shown in Fig. 6. The relationship was linear and highly significant, with a Pearson correlation



**Table II.** Types of Substitutions in Rearranged V<sub>H</sub>6 Genes<sup>a</sup>

Substitution	% total <sup>b</sup>		% silent <sup>c</sup>	
	Young (n = 450)	Old (n = 569)	Young (n = 68)	Old (n = 67)
A to				
G	20	20	24	13
T	9	8	8	5
C	9	10	9	13
T to				
C	10	8	24	26
A	6	4	0	5
G	4	3	4	0
C to				
T	14	14	4	8
A	1	3	3	1
G	7	7	4	8
G to				
A	9	11	4	8
T	3	3	4	3
C	8	9	12	10

<sup>a</sup>Data are corrected for base composition, so that the numbers represent the percentage substitutions expected from a sequence with equal numbers of A, T, C, and G.

<sup>b</sup>Includes all replacement and silent substitutions.

<sup>c</sup>Silent substitutions in the eight codons with threefold wobble in the third position.

coefficient of 0.91 ( $P = 0.0004$ ); the Spearman rank correlation gave similar results. Table III also summarizes the mutation data per individual; there was no significant correlation between the frequency of microsatellite changes and either the mutation frequency (Pearson correlation coefficient of 0.25,  $P = 0.48$ ) or the percentage of G and C mutations (Pearson correlation coefficient of 0.06,  $P = 0.85$ ).

## DISCUSSION

### *Old Humans Express Highly Mutated Antibodies*

Young humans had more hypermutated cDNA clones than old humans, confirming that some aspects of cellular immunity decline with age (reviewed in Ref. 40). However, among the mutated clones, the frequencies of mutation were very similar between the young (2.4% mutations/bp) and the old (2.8% mutations/bp) groups. The frequency of mutation in rearranged V<sub>H</sub>6 gene segments is similar to that obtained in a study of other genes in V<sub>H</sub> families 1–7 (18) and, therefore, reflects a general property of V<sub>H</sub> genes in IgM transcripts from peripheral blood B cells. The location of mutations in the FRs and CDRs and the types of substitutions were also identical between the two groups. Thus, even though the old population had fewer B cells with mutation, it is likely that they have the ability to mount an adequate

humoral immune response because of strong selection for those cells expressing mutated antibodies.

It is not known whether the mutations in clones from old people were induced by the mutation mechanism in naive B cells or were already present in long-lived memory cells. There is evidence supporting both pathways in humans. B cells with unmutated V genes are frequently found in the peripheral blood of old people (13, 18), and they likely arise from newly generated cells in bone marrow (41). Long-lived memory B cells expressing IgM with heavily mutated genes are also readily detected in peripheral blood (42, 43). Another possibility is that V genes in memory cells undergo further mutation upon repeated rounds of antigen encounters (11). The data in this report are consistent with participation from both naive and memory cells in old people. Thus, the clones in Fig. 1 with a few mutations and no replacement changes in CDRs1 and 2 may have derived from recently mutated, unselected B cells. The clones with many mutations may have come from memory cells that have undergone years of selection and expansion for binding to antigen.

### *Antibodies from Old Humans Are Highly Selected in CDRs*

Although the young and old groups had the same frequency of mutation in CDRs and FRs (Fig. 2), selection for those substitutions leading to replacement amino acids in the CDRs was strikingly enhanced in genes from the old group (Fig. 4). The cDNA clones likely came from the abundant RNA made by plasma cells that were generated from recently-stimulated naive or memory B cells (44). It is not known if this difference is due to aging or recent exposure to antigen. The prevalence of nine tyrosine-to-phenylalanine changes at residue 56 in CDR2 in all five old individuals compared to only once in a young person suggests that the old group was exposed to at least one common antigen that the young group did not encounter. The specificity of these V<sub>H</sub>6-encoded antibodies is unknown since the corresponding light chains were not identified. In general, V<sub>H</sub>6-encoded antibodies are polyreactive and have been shown to bind bacteria, DNA, and cardiolipin (45–47), suggesting that the old people were undergoing an autoimmune reaction. It is also possible that some of these antibodies bind influenza antigens, since the old people recently received influenza vaccinations and the young people did not. The vaccination status would also explain why a similar study on V<sub>H</sub>6 genes in unimmunized old subjects failed to show selection for replacement changes in the CDRs (12). However, the age-




Fig. 4. Replacement-to-silent substitution ratios in  $V_H6$  gene segments in clones from young and old humans. Bars represent the average ratios calculated for 2–10 codon increments.

related impact of immunization on the mutation frequency cannot be evaluated in the present study because the young subjects were not vaccinated.

#### *Tandem Mutations in V Genes Correlate with Microsatellite Variability*

Recent experiments by several groups have reported altered patterns of mutation in V genes from mice deficient for several mismatch repair proteins. Mice deficient in MSH2, a protein that binds to mismatches, have an increased number of mutations of G and C nucleotides (48–51), and we observed that mice deficient in PMS2, a protein that combines with MSH2 and other proteins to excise mismatches, have an increased number of tandem mutations (23). Other groups studying mutation in PMS2-deficient mice did not detect an increased

number of tandem mutations (50, 52–54); however, their data were limited to 3–13 clones per study with two or more mutations, whereas our analysis included 30 clones. The data suggest that an error-prone DNA polymerase functions during hypermutation to generate mismatched base pairs, and some of these are corrected by the mismatch repair pathway. To see if the mutational spectra changes with age in humans, we analyzed unselected silent and FR mutations for these two parameters. There was no difference between the young and the old groups in the frequency of mutations of G and C or in the frequency of tandem pairs. However, since there was a broad range in the data, a correlation with mismatch repair may exist on an individual basis.

Lymphocyte DNA was then examined for microsatellite variability, which is known to accumulate in cells with defective mismatch repair (5). Insertions and dele-

**Table III.** Hypermutation and Microsatellite Changes per Individual

	Total frequency mutations/bp (%)	Silent mutations of G and C <sup>a</sup> (%)	FR tandems (observed/expected) ratio	Microsatellite variability, % (altered/total) <sup>b</sup>
Young				
Y1	2.4	36	0 (0/0.86)	1.3 (1/79)
Y3	2.1	13	0.8 (1/1.28)	2.2 (2/92)
Y4	2.4	43	1.6 (2/1.22)	3.9 (3/77)
Y5	2.6	25	2.0 (5/2.48)	3.4 (3/87)
Y2	2.6	56	3.1 (3/0.96)	3.4 (3/89)
Old				
O1	3.7	51	0 (0/1.22)	1.1 (1/93)
O3	3.0	26	1.9 (3/1.62)	2.9 (2/68)
O2	4.0	49	2.0 (9/4.54)	4.4 (4/91)
O4	2.3	38	4.4 (4/0.92)	5.6 (4/72)
O5	1.9	32	4.9 (6/1.22)	5.3 (4/76)


<sup>a</sup>From Table II.<sup>b</sup>Number of reactions with microsatellite bands of different mobilities divided by total number of positive reactions.

tions are occasionally introduced during replication when DNA polymerase slips on repetitive sequences and misaligns on the template, and the length variations are usually removed by the mismatch repair pathway. If the pathway is compromised, the insertions and deletions remain and are copied into the cell's genome. An analysis of the length variation of the S123 dinucleotide satellite marker revealed a range of 1–6% alterations in peripheral blood cells from both young and old populations, with no difference between the two groups. This detection of microsatellite variability in a heterogeneous population of B and T cells from healthy donors is remarkable considering that microsatellite variations in T-cell clones from healthy individuals is only 0.3% (55). Per individual, there was no correlation between the

frequency of altered microsatellites and mutations of G and C. However, a plot of the frequency of altered microsatellites vs tandem mutations in all 10 subjects showed a very significant correlation ( $P < 10^{-3}$ ; Fig. 6), which indicates that the two phenomena are related. Thus, an increased frequency of tandem mutations may serve as a marker for altered mismatch repair function.

#### *Tandem Mutations May Be Generated During One Passage of an Error-Prone DNA Polymerase*

Base substitutions have been shown to accumulate at the nucleotide motifs RGYW and its inverse complement, WRCY (33–35). Approximately 24% of the nucleotides in FRs 1–4 in V<sub>H</sub>6 and J<sub>H</sub> gene segments are in



**Fig. 5.** Microsatellite variability in peripheral blood DNA. Examples of variability and polymorphism for the S123 locus are shown for subjects with homozygous alleles (Y1) and heterozygous alleles differing by 2 bp (O2), 4 bp (O5), and 10 bp (O4). Arrowheads indicate the position of the major PCR products from undiluted template DNA, and asterisks mark the lanes with insertions or deletions.




Fig. 6. Correlation of tandem mutations and microsatellite variability. Values from young individuals are shown by open circles, and values from old individuals are shown by filled squares.

RGYW/WRCY sequences (underlined in Figs. 1 and 3), whereas 70% (23/33) of the tandem pairs were in these sequences. This indicates that the tandem mutations were targeted to the hot spot motifs. Adjacent mutations may occur consecutively during each round of repair and/or simultaneously during one round of repair (56). The following reasons imply that many of them could be generated during one passage of an error-prone DNA polymerase. First, if two mutations occurred singly within the four-4 nucleotide motif, half of the mutations would be tandem by chance. Within this data set, 12.5 tandem mutations would be expected to occur by chance, whereas 23 were observed. Thus, tandem mutations occurred significantly more often than would be expected from two individual events ( $P < 10^{-4}$ ), suggesting that many of them arose from a single event. Second, a single mutation may destroy an existing hot spot or create a new one. For example, clone O4-8043 has a tandem mutation, TC, at codon 3 within an RGYW hot spot (Fig. 1). Both mutations would destroy the hot spot if they occurred singly: if the T mutation occurred first, the sequence would become TGYW, and if the C

mutation occurred first, the sequence would become RCYW. Alternatively, clone Y4-7107 has a tandem mutation, TT, at codon 10 that is not in a hot spot. The first T mutation would create a RGYW hot spot that could attract the second T mutation. The data in this study were analyzed by these parameters. If paired mutations occurred one at a time within a hot spot, 33% of the mutations would keep the motif and 67% would destroy it. If they occurred singly outside of a hot spot, 20% would create a new hot spot and 80% would not. Thus, two successive mutations are more likely to destroy a hot spot than to keep the motif or create a new hot spot. Third, some of the newly described DNA polymerases are able to catalyze two adjacent misincorporations into undamaged DNA at an unusually high frequency, and can extend from two mismatches (57-59). With such an error-prone polymerase, tandem mutations may likely arise during a single event that is targeted to a strand break within a hot-spot sequence. At the protein level, there seems to be no obvious advantage or disadvantage to having tandem DNA mutations vs. single mutations in changing codons.

## Conclusions

There were fewer mutated heavy chains expressed by peripheral blood B cells from old people compared to young people, indicating that the immune response declines with age. However, among the mutated V genes, the frequency and pattern of mutation were similar between the two groups, which suggests that people can mount an adequate humoral response to antigens well into the ninth decade of life. This was confirmed by strong selection for mutations that changed amino acids in the CDRs in clones from old humans. There was no change in the overall frequency of microsatellite alterations in lymphocyte DNA with age; although there was variability on an individual level. A correlation between the frequency of microsatellite alterations and tandem mutations in V genes suggests that individuals vary in their DNA mismatch repair capacity.

## ACKNOWLEDGMENTS

We thank Jeff Metter and Howard Baldwin for assistance with samples from the Baltimore Longitudinal Study on Aging, Iris van Dijk-Hard for unpublished data, and Rick Wood and Rebecca Selzer for valuable comments on the manuscript. We appreciate support from the Danish Center for Molecular Gerontology at the University of Copenhagen.

## REFERENCES

- Johnson FB, Sinclair DA, Guarente L: Molecular biology of aging. *Cell* 96:291–302, 1999
- Jackson AL, Loeb LA: On the origin of multiple mutations in human cancers. *Semin Cancer Biol* 8:421–429, 1998
- Bohr VA, Anson RM: Mitochondrial DNA repair pathways. *J Bioenerg Biomembr* 31:391–398, 1999
- Lindahl T, Wood RD: Quality control by DNA repair. *Science* 286:1897–1905, 1999
- Buermeyer AB, Deschenes SM, Baker SM, Liskay RM: Mammalian DNA mismatch repair. *Annu Rev Genet* 33:533–564, 1999
- Moriwaki SI, Ray S, Tarone RE, Kraemer KH, Grossman L: The effect of donor age on the processing of UV-damaged DNA by cultured human cells: Reduced DNA capacity and increased DNA mutability. *Mutat Res DNA Repair* 364:117–123, 1996
- Winter DB, Gearhart PJ: Dual enigma of somatic hypermutation of immunoglobulin variable genes: targeting and mechanism. *Immunol Rev* 162:89–96, 1998
- Miller C, Kelsoe G: IgV<sub>H</sub> hypermutation is absent in the germinal centers of aged mice. *J Immunol* 155:3377–3384, 1995
- Yang X, Stedra J, Cerny J: Relative contribution of T and B cells to hypermutation and selection of the antibody repertoire in germinal centers of aged mice. *J Exp Med* 83:959–970, 1996
- LeMaout J, Szabo P, Weksler ME: Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development. *Immunol Rev* 160:115–126, 1997
- Gonzalez-Fernandez A, Gilmore D, Milstein C: Age-related decrease in the proportion of germinal center B cells from mouse Peyer's patches is accompanied by an accumulation of somatic mutations in their immunoglobulin genes. *Eur J Immunol* 24:2918–2921, 1994
- Williams GT, Jolly CJ, Kohler J, Neuberger MS: The contribution of somatic hypermutation to the diversity of serum immunoglobulin: Dramatic increase with age. *Immunity* 13:409–417, 2000
- Klein U, Kuppers R, Rajewsky K: Human IgM<sup>+</sup>IgD<sup>+</sup> B cells, the major B cell subset in the peripheral blood, express V<sub>κ</sub> genes with no or little somatic mutation throughout life. *Eur J Immunol* 23:3272–3277, 1993
- van Dijk-Hard I, Soderstrom I, Feld S, Holmberg D, Lundkvist I: Age-related impaired affinity maturation and differential D-J<sub>H</sub> gene usage in human V<sub>H</sub>6-expressing B lymphocytes from healthy individuals. *Eur J Immunol* 27:1381–1386, 1997
- Troutaud D, Drouet M, Decourt C, Le Morvan C, Cogne M: Age-related alterations of somatic hypermutation and CDR3 lengths in human V<sub>κ</sub>4-expressing B lymphocytes. *Immunology* 97:197–203, 1999
- Klein R, Jaenichen R, Zachau HG: Expressed human immunoglobulin κ genes and their hypermutation. *Eur J Immunol* 23:3248–3271, 1993
- Bridges SL Jr, Lee SK, Johnson ML, Lavelle JC, Fowler PG, Koopman WJ, Schroeder HW Jr: Somatic mutation and CDR3 lengths of immunoglobulin κ light chains expressed in patients with rheumatoid arthritis and in normal individuals. *J Clin Invest* 96:831–841, 1995
- Wang X, Stollar BD: Immunoglobulin VH gene expression in human aging. *Clin Immunol* 93:132–142, 1999
- Dunn-Walters DK, Boursier L, Spencer J: Hypermutation, diversity and dissemination of human intestinal lamina propria plasma cells. *Eur J Immunol* 27:2959–2964, 1997
- Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C: Sequences of Proteins of Immunological Interest, 5th ed. Bethesda, MD, U.S. Department of Health and Human Services, 1991
- Berman JE, Mellis SJ, Pollock R, Smith CL, Suh H, Heinke B, Kowal C, Surti U, Chess L, Cantor CR, Alt FW: Content and organization of the human Ig V<sub>H</sub> locus: Definition of three new V<sub>H</sub> families and linkage to the Ig C<sub>H1</sub> locus. *EMBO J* 7:727–738, 1988
- Parsons R, Li G-M, Longley M, Modrich P, Liu B, Berk T, Hamilton ST, Kinzler KW, Vogelstein B: Mismatch repair deficiency in phenotypically normal human cells. *Science* 268:738–740, 1995
- Winter DB, Phung QH, Umar A, Baker SM, Tarone RE, Tanaka K, Liskay RM, Kunkel TA, Bohr VA, Gearhart PJ: Altered spectra of hypermutation in antibodies from mice deficient for the DNA mismatch repair protein PMS2. *Proc Natl Acad Sci USA* 95:6953–6958, 1998
- Sanz I, Kelly P, Williams C, Scholl S, Tucker P, Capra JD: The smaller human V<sub>H</sub> gene families display remarkably little polymorphism. *EMBO J* 8:3741–3748, 1989
- Yamada M, Wasserman R, Reichard BA, Shane S, Caton AJ, Rovera G: Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes. *J Exp Med* 173:395–407, 1991
- Huang C, Stewart AK, Schwartz RS, Stollar BD: Immunoglobulin heavy chain gene expression in peripheral blood B lymphocytes. *J Clin Invest* 89:1331–1343, 1992
- van Es JH, Gmelig Meyling FHJ, Logtenberg T: High frequency of somatically mutated IgM molecules in the human adult blood B cell repertoire. *Eur J Immunol* 22:2761–2764, 1992

28. Wu H, Pelkonen E, Knuutila S, Kaartinen M: A human follicular lymphoma B cell line hypermutates its functional immunoglobulin genes *in vitro*. *Eur J Immunol* 25:3263–3269, 1995
29. Wilson PC, de Bouteiller O, Liu Y-J, Potter K, Banchereau J, Capra JD, Pascual V: Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes. *J Exp Med* 187:59–70, 1998
30. Goossens T, Klein U, Kuppers R: Frequent occurrence of deletions and duplications during somatic hypermutation: Implications for oncogene translocations and heavy chain disease. *Proc Natl Acad Sci USA* 95:2463–2468, 1998
31. Xue W, Luo S, Adler WH, Schulze DH, Berman JE: Immunoglobulin heavy chain junctional diversity in young and aged humans. *Hum Immunol* 57:80–92, 1997
32. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G: Structural repertoire of the human V<sub>H</sub> segments. *J Mol Biol* 227:799–817, 1992
33. Rogozin IB, Kolchanov NA: Somatic hypermutagenesis in immunoglobulin genes. Influence of neighbouring base sequences on mutagenesis. *Biochim Biophys Acta* 1171:11–18, 1992
34. Wagner SD, Milstein C, Neuberger MS: Codon bias targets mutation. *Nature* 376:732, 1995
35. Shapiro GS, Aviszus K, Ikle D, Wysocki LJ: Predicting regional mutability in antibody genes based solely on di- and trinucleotide sequence composition. *J Immunol* 163:259–268, 1999
36. Papavasiliou FN, Schatz DG: Cell-cycle-regulated DNA double-strand breaks in somatic hypermutation of immunoglobulin genes. *Nature* 408:216–221, 2000
37. Bross L, Fukita Y, McBlane F, Demolliere C, Rajewsky K, Jacobs H: DNA double-strand breaks in immunoglobulin genes undergoing somatic hypermutation. *Immunity* 13:589–597, 2000
38. Insel RA, Varade WS: Bias in somatic hypermutation of human V<sub>H</sub> genes. *Int Immunol* 6:1437–1443, 1994
39. Klein U, Kuppers R, Rajewsky K: Variable region gene analysis of B cell subsets derived from a 4-year old child: Somatic mutation memory B cells accumulate in the peripheral blood already at young age. *J Exp Med* 180:1383–1393, 1994
40. Aging and the immune system. *Immunol Rev* 160:5–184, 1997
41. Nunez C, Nishimoto N, Gartland GL, Billips LG, Burrows PD, Kubagawa H, Cooper MD: B cells are generated throughout life in humans. *J Immunol* 156:866–872, 1996
42. Klein U, Kuppers R, Rajewsky K: Evidence for a large compartment of IgM-expressing memory B cells in humans. *Blood* 89:1288–1298, 1997
43. Klein U, Rajewsky K, Kuppers R: Human immunoglobulin (Ig)M<sup>+</sup>IgD<sup>+</sup> peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. *J Exp Med* 188:1679–1689, 1998
44. Kelley DE, Perry RP: Transcriptional and posttranscriptional control of immunoglobulin mRNA production during B lymphocyte development. *Nucleic Acids Res* 14:5431–5447, 1986
45. Logtenberg T, Young FM, van Es JH, Gmelig-Meyling FH, Alt FW: Autoantibodies encoded by the most J<sub>H</sub>-proximal human immunoglobulin heavy chain variable region gene. *J Exp Med* 170:1347–1355, 1989
46. Settmacher U, Jahn S, Siegel P, von Baehr R, Hansen A: An anti-lipid A antibody obtained from the human fetal repertoire is encoded by V<sub>H</sub>6-V<sub>A</sub>1 genes. *Mol Immunol* 30:953–954, 1993
47. Andris JS, Brodeur BR, Capra JD: Molecular characterization of human antibodies to bacterial antigens: utilization of the less frequently expressed V<sub>H</sub>2 and V<sub>H</sub>6 heavy chain variable region gene families. *Mol Immunol* 30:1601–1616, 1993
48. Phung QH, Winter DB, Cranston A, Tarone RE, Bohr VA, Fishel R, Gearhart PJ: Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. *J Exp Med* 187:1745–1751, 1998
49. Jacobs H, Fukita Y, van der Horst GTJ, de Boer J, Weeda G, Essers J, de Wind N, Engelward BP, Samson L, Verbeek S, de Murcia JM, de Murcia G, te Riele H, Rajewsky K: Hypermutation of immunoglobulin genes in memory B cells of DNA repair-deficient mice. *J Exp Med* 187:1735–1743, 1998
50. Frey S, Bertocci B, Delbos F, Quint L, Weill J-C, Reynaud C-A: Mismatch repair deficiency interferes with the accumulation of mutations in chronically stimulated B cells and not with the hypermutation process. *Immunity* 9:127–134, 1998
51. Rada C, Ehrenstein MR, Neuberger MS, Milstein C: Hot spot focusing of somatic hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. *Immunity* 9:135–141, 1998
52. Cascalho M, Wong J, Steinberg C, Wabl M: Mismatch repair co-opted by hypermutation. *Science* 279:1207–1210, 1998
53. Kong Q, Maizels N: PMS2-deficiency diminishes hypermutation of a  $\lambda_1$  transgene in young but not older mice. *Mol Immunol* 36:83–91, 1999
54. Kim N, Bozek G, Lo JC, Storb U: Different mismatch repair deficiencies all have the same effects on somatic hypermutation: Intact primary mechanism accompanied by secondary modifications. *J Exp Med* 190:21–30, 1999
55. Hackman P, Gabbani G, Osterholm AM, Hellgren D, Lambert B: Spontaneous length variation in microsatellite DNA from human T-cell clones. *Genes Chromosomes Cancer* 14:215–219, 1995
56. Gearhart PJ, Bogenhagen DF: Clusters of point mutations are found exclusively around rearranged antibody variable genes. *Proc Natl Acad Sci USA* 80:3439–3443, 1983
57. Domínguez O, Ruiz JF, Lain De Lera T, García-Díaz M, González MA, Kirchhoff T, Martínez-A C, Bernad A, Blanco L: DNA polymerase  $\mu$  (Pol  $\mu$ ), homologous to TdT, could act as a DNA mutator in eukaryotic cells. *EMBO J* 19:1731–1742, 2000
58. Matsuda T, Bebenek K, Masutani C, Hanaoka F, Kunkel TA: Low fidelity DNA synthesis by human DNA polymerase- $\eta$ . *Nature* 404:1011–1013, 2000
59. Tissier A, McDonald JP, Frank EG, Woodgate R: Pol $\epsilon$ , a remarkably error-prone human DNA polymerase. *Genes Dev* 14:1642–1650, 2000